MONMOUTH JUNCTION, N.J., Aug. 7, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, reports financial and operational results for the quarter ending June 30, 2017.
Second Quarter 2017 Financial Highlights:
Total Q2 2017 revenues increased 60% to $3.6 million, which includes both product sales and grant income, up
Second Quarter 2017 Financial Highlights:
Total Q2 2017 revenues increased 60% to $3.6 million, which includes both product sales and grant income, up
